Literature DB >> 25336209

Amphetamine in adolescence disrupts the development of medial prefrontal cortex dopamine connectivity in a DCC-dependent manner.

Lauren M Reynolds1, Carolina S Makowski1, Sandra V Yogendran1, Silke Kiessling2, Nicolas Cermakian2, Cecilia Flores3.   

Abstract

Initiation of drug use during adolescence is a strong predictor of both the incidence and severity of addiction throughout the lifetime. Intriguingly, adolescence is a period of dynamic refinement in the organization of neuronal connectivity, in particular medial prefrontal cortex (mPFC) dopamine circuitry. The guidance cue receptor, DCC (deleted in colorectal cancer), is highly expressed by dopamine neurons and orchestrates their innervation to the mPFC during adolescence. Furthermore, we have shown that amphetamine in adolescence regulates DCC expression in dopamine neurons. Drugs in adolescence may therefore induce their enduring behavioral effects via DCC-mediated disruption in mPFC dopamine development. In this study, we investigated the impact of repeated exposure to amphetamine during adolescence on both the development of mPFC dopamine connectivity and on salience attribution to drug context in adulthood. We compare these effects to those induced by adult exposure to an identical amphetamine regimen. Finally, we determine whether DCC signaling within dopamine neurons is necessary for these events. Exposure to amphetamine in adolescence, but not in adulthood, leads to an increase in the span of dopamine innervation to the mPFC, but a reduction of presynaptic sites present on these axons. Amphetamine treatment in adolescence, but not in adulthood, also produces an increase in salience attribution to a previously drug-paired context in adulthood. Remarkably, DCC signaling within dopamine neurons is required for both of these effects. Drugs of abuse in adolescence may therefore induce their detrimental behavioral consequences by disrupting mesocortical dopamine development through alterations in the DCC signaling cascade.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25336209      PMCID: PMC4367452          DOI: 10.1038/npp.2014.287

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  82 in total

1.  Brain development during childhood and adolescence: a longitudinal MRI study.

Authors:  J N Giedd; J Blumenthal; N O Jeffries; F X Castellanos; H Liu; A Zijdenbos; T Paus; A C Evans; J L Rapoport
Journal:  Nat Neurosci       Date:  1999-10       Impact factor: 24.884

2.  Localization of immunoreactivity for deleted in colorectal cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents.

Authors:  P B Osborne; G M Halliday; H M Cooper; J R Keast
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  Executive dysfunction in substance dependent individuals during drug use and abstinence: an examination of the behavioral, cognitive and emotional correlates of addiction.

Authors:  Antonio Verdejo-García; Antoine Bechara; Emily C Recknor; Miguel Pérez-García
Journal:  J Int Neuropsychol Soc       Date:  2006-05       Impact factor: 2.892

Review 4.  Review. The incentive sensitization theory of addiction: some current issues.

Authors:  Terry E Robinson; Kent C Berridge
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-10-12       Impact factor: 6.237

5.  Age of onset of drug use and its association with DSM-IV drug abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey.

Authors:  B F Grant; D A Dawson
Journal:  J Subst Abuse       Date:  1998

6.  Early-onset drug use and risk of later drug problems.

Authors:  J C Anthony; K R Petronis
Journal:  Drug Alcohol Depend       Date:  1995-11       Impact factor: 4.492

7.  The substance use profile of Canadian youth: exploring the prevalence of alcohol, drug and tobacco use by gender and grade.

Authors:  Scott T Leatherdale; Robin Burkhalter
Journal:  Addict Behav       Date:  2011-10-19       Impact factor: 3.913

8.  The netrin receptor DCC is required in the pubertal organization of mesocortical dopamine circuitry.

Authors:  Colleen Manitt; Andrea Mimee; Conrad Eng; Matthew Pokinko; Thomas Stroh; Helen M Cooper; Bryan Kolb; Cecilia Flores
Journal:  J Neurosci       Date:  2011-06-08       Impact factor: 6.167

9.  Netrin-1 receptor-deficient mice show enhanced mesocortical dopamine transmission and blunted behavioural responses to amphetamine.

Authors:  Alanna Grant; Daniel Hoops; Cassandre Labelle-Dumais; Michael Prévost; Heshmat Rajabi; Bryan Kolb; Jane Stewart; Andreas Arvanitogiannis; Cecilia Flores
Journal:  Eur J Neurosci       Date:  2007-11-14       Impact factor: 3.386

10.  Abnormal structure of frontostriatal brain systems is associated with aspects of impulsivity and compulsivity in cocaine dependence.

Authors:  Karen D Ersche; Anna Barnes; P Simon Jones; Sharon Morein-Zamir; Trevor W Robbins; Edward T Bullmore
Journal:  Brain       Date:  2011-06-20       Impact factor: 13.501

View more
  30 in total

1.  Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.

Authors:  David A Connor; Thomas J Gould
Journal:  Neuropharmacology       Date:  2017-08-02       Impact factor: 5.250

Review 2.  The Netrin-1/DCC Guidance Cue Pathway as a Molecular Target in Depression: Translational Evidence.

Authors:  Angélica Torres-Berrío; Giovanni Hernandez; Eric J Nestler; Cecilia Flores
Journal:  Biol Psychiatry       Date:  2020-05-11       Impact factor: 13.382

Review 3.  Neurobehavioral changes arising from early life dopamine signaling perturbations.

Authors:  Lorena B Areal; Randy D Blakely
Journal:  Neurochem Int       Date:  2020-04-20       Impact factor: 3.921

4.  Effects of amphetamine exposure during adolescence on behavior and prelimbic cortex neuron activity in adulthood.

Authors:  Luke K Sherrill; Joshua M Gulley
Journal:  Brain Res       Date:  2018-05-21       Impact factor: 3.252

5.  DCC Confers Susceptibility to Depression-like Behaviors in Humans and Mice and Is Regulated by miR-218.

Authors:  Angélica Torres-Berrío; Juan Pablo Lopez; Rosemary C Bagot; Dominique Nouel; Gregory Dal Bo; Santiago Cuesta; Lei Zhu; Colleen Manitt; Conrad Eng; Helen M Cooper; Kai-Florian Storch; Gustavo Turecki; Eric J Nestler; Cecilia Flores
Journal:  Biol Psychiatry       Date:  2016-08-18       Impact factor: 13.382

6.  Early Adolescence is a Critical Period for the Maturation of Inhibitory Behavior.

Authors:  Lauren M Reynolds; Leora Yetnikoff; Matthew Pokinko; Michael Wodzinski; Julia G Epelbaum; Laura C Lambert; Marie-Pierre Cossette; Andreas Arvanitogiannis; Cecilia Flores
Journal:  Cereb Cortex       Date:  2019-08-14       Impact factor: 5.357

Review 7.  AMPed-up adolescents: The role of age in the abuse of amphetamines and its consequences on cognition and prefrontal cortex development.

Authors:  Sara R Westbrook; Lauren K Carrica; Asia Banks; Joshua M Gulley
Journal:  Pharmacol Biochem Behav       Date:  2020-08-20       Impact factor: 3.533

Review 8.  Adolescence and Reward: Making Sense of Neural and Behavioral Changes Amid the Chaos.

Authors:  Deena M Walker; Margaret R Bell; Cecilia Flores; Joshua M Gulley; Jari Willing; Matthew J Paul
Journal:  J Neurosci       Date:  2017-11-08       Impact factor: 6.167

9.  Repeated exposure to amphetamine during adolescence alters inhibitory tone in the medial prefrontal cortex following drug re-exposure in adulthood.

Authors:  Kush Paul; Shuo Kang; Charles L Cox; Joshua M Gulley
Journal:  Behav Brain Res       Date:  2016-04-13       Impact factor: 3.332

10.  DCC Receptors Drive Prefrontal Cortex Maturation by Determining Dopamine Axon Targeting in Adolescence.

Authors:  Lauren M Reynolds; Matthew Pokinko; Angélica Torres-Berrío; Santiago Cuesta; Laura C Lambert; Esther Del Cid Pellitero; Michael Wodzinski; Colleen Manitt; Paul Krimpenfort; Bryan Kolb; Cecilia Flores
Journal:  Biol Psychiatry       Date:  2017-06-16       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.